TY  - JOUR

TI  - Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results
JO  - The Clinical Lung Cancer
PY  - 2026
DO  - 10.52338/tclc.2024.1002
ER  -